S'abonner

Efficacy and safety comparison: Fluticasone furoate and fluticasone propionate, after step down from fluticasone furoate/vilanterol in Japanese patients with well-controlled asthma, a randomized trial - 04/11/16

Doi : 10.1016/j.rmed.2016.09.018 
Mitsuru Adachi a, Caroline Goldfrad b, Loretta Jacques c, Yoshie Nishimura d, ⁎
a Department of Clinical Research Centers, International University of Health and Welfare/Sanno Hospital, 10–16, Akasaka 8-chome, Minato-ku, Tokyo, 107-0052, Japan 
b Quantitative Sciences Division, GSK, London, TW8 9GS, UK 
c Respiratory Medicine Discovery and Development, GSK, London, TW8 9GS, UK 
d Development & Medical Affairs Medicines Development Respiratory TA Office, GSK, 6-15, Sendagaya 4-chome, Shibuya-ku, Tokyo, 151-8566, Japan 

∗Corresponding author.

Abstract

Background

For patients with well-controlled asthma, ‘step down’ of therapy is recommended. We evaluated Japanese patients switching from inhaled corticosteroid (ICS)/long-acting beta2-agonists (LABA; equivalent to fluticasone propionate [FP]/salmeterol [SAL] 250/50 μg twice daily [BD]) to fluticasone furoate (FF)/vilanterol (VI) 100/25 μg, then stepping down to ICS alone.

Methods

This phase III trial had two treatment periods (P): P1, patients with well-controlled asthma on FP/SAL 250/50 μg BD equivalent stepped across to once daily (OD) FF/VI 100/25 μg (open-label, eight weeks); P2, patients remaining ‘well controlled’ after P1 stepped down to FF 100 μg OD/FP 100 μg BD/FP 250 μg BD (randomized 1:1:1, double-blind, 12 weeks). Co-primary P2 endpoints: percentage of patients with well-controlled asthma; time to withdrawal due to poorly controlled asthma requiring step-up therapy. Adverse events (AEs) were monitored.

Results

At the end of P1 (n = 430), 373/415 (89.9%; 95% confidence interval 86.57–92.61) patients' asthma remained well controlled with FF/VI; in P2 (n = 371), control was maintained in 89.5% (FF 100 μg)/78.2% (FP 100 μg)/83.1% (FP 250 μg) of patients. In P2, 4.9–8.1% of patients were withdrawn due to worsening asthma (time-to-withdrawal cumulative incidence curves were comparable). AEs were reported by 37% of patients during P1; and by 36% (FF 100 μg)/48% (FP 100 μg)/49% (FP 250 μg) of patients in P2.

Conclusions

For patients with well-controlled asthma on mid dose ICS/LABA (equivalent to FP/SAL 250/50 μg BD), control can be maintained when they are stepped across to FF/VI 100/25 μg OD. FF 100 μg OD is an effective step-down therapy from FF/VI 100/25 μg OD with similar efficacy to FP 100 μg BD and FP 250 μg BD.

Le texte complet de cet article est disponible en PDF.

Highlights

•
Study conducted in Japanese pts with well-controlled asthma on mid dose ICS/LABA.
•
90.5% of pts maintain control on switch from mid dose ICS/LABA to FF/VI 100/25OD.
•
Similar efficacy of FF100OD, FP100BD and FP250BD on step down from FF/VI 100/25OD.

Le texte complet de cet article est disponible en PDF.

Keywords : Asthma, Well-controlled asthma, Inhaled corticosteroid, Long-acting beta2-agonist, ‘Step down’ of asthma therapy, ‘Step across’ of asthma therapy


Plan


© 2016  The Authors. Publié par Elsevier Masson SAS. Tous droits réservés.
Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 120

P. 78-86 - novembre 2016 Retour au numéro
Article précédent Article précédent
  • Subjects with well-controlled asthma have similar health-related quality of life as subjects without asthma
  • Sven-Arne Jansson, Malin Axelsson, Linnea Hedman, Mai Leander, Caroline Stridsman, Eva Rönmark
| Article suivant Article suivant
  • Drug-related problems and pharmacist interventions in a cohort of patients with asthma and chronic obstructive pulmonary disease
  • Sule Apikoglu-Rabus, Gozde Yesilyaprak, Fikret Vehbi Izzettin

Déjà abonné à cette revue ?